A pilot, multicenter, open-label, one-group study to explore the effic
A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Glatiramer acetate
Unknown
What it measured
Main measures
Primary efficacy endpoint:
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: 1. Clinically Definite Multiple Sclerosis (CDMS) as defined by Poser et al (Ann Neurol 1983;13:227-231) Exclusion: 1. Pregnancy or lactation
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate the effect of a daily oral dose of 600 mg glatiramer acetate on MRI disease activity as measured by the total number of T1 gadolinium-enhancing lesions in subjects with relapsing-remitting multiple sclerosis.
Loading reviews and guidelines…
Related trials
- Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting
Phase 3 · Not yet recruiting
Still running
- A NIS Evaluating Various Injectable and Oral Treatments in Patients Wi
Recruiting
Still running
- Discontinuation of first-line disease modifying treatment (DMT) in lon
Phase 4 · Stopped early
Stopped
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY
Running, not recruiting
Still running
- A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple
Phase 4 · Stopped early
Stopped: safety
- A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-act
Phase 3 · Completed
Met its main goal
History
Started
Jul 2004